Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 24NIH 10OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 2Gastrointestinal 2Thoracic 1

Conditions

Mesothelioma, Malignant 1Malignant Solid Tumour 1Colorectal Cancer Metastatic 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × ARQ 197 × Clear all
NCT01892527 2022-09-09

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Istituto Clinico Humanitas

Phase 2 Completed
43 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT02049060 2021-01-22

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

Istituto Clinico Humanitas

Phase 1/2 Completed
31 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01611857 2016-11-23

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

SCRI Development Innovations, LLC

Phase 1/2 Completed
49 enrolled 12 charts
GastrointestinalOther solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡